Ra Pharmaceuticals (RARX) Form 3 Ra Pharmaceuticals / Alonso Ricardo ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Ricardo Alonso

(Last) (First) (Middle)

C/O RA PHARMACEUTICALS, INC.

87 CAMBRIDGEPARK DRIVE

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/24/2019

3. Issuer Name and Ticker or Trading Symbol
Ra Pharmaceuticals, Inc. [ RARX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	14,285	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	(1)	06/14/2022	Common Stock	2,857	0.84	D
Option to Purchase Common Stock	(1)	12/11/2024	Common Stock	14,285	2.87	D
Option to Purchase Common Stock	(2)	12/10/2025	Common Stock	30,000	2.87	D
Option to Purchase Common Stock	(3)	08/16/2026	Common Stock	31,428	5.6	D
Option to Purchase Common Stock	(4)	02/01/2027	Common Stock	60,000	16.64	D
Option to Purchase Common Stock	(5)	02/01/2028	Common Stock	26,250	7.33	D
Option to Purchase Common Stock	(6)	02/01/2029	Common Stock	107,000	21	D
Restricted Stock Units	(7)	(8)	Common Stock	8,750	0(9)	D

Explanation of Responses:

1. The shares underlying these options are fully vested and exercisable.

2. These stock options vest in 48 equal monthly installments on each monthly anniversary following December 10, 2015, the grant date.

3. These stock options vest in 48 equal monthly installments on each monthly anniversary following August 16, 2016, the grant date.

4. These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2017, the grant date.

5. These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2018, the grant date.

6. These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date.

7. On February 1, 2018, the reporting person was granted 13,125 restricted stock units, which have vested and settled or will vest and settle in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021.

8. Not applicable.

9. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Remarks:

Title: Chief Technology and Innovation Officer, and Head of Research Exhibit 24.1: Limited Power of Attorney

	/s/ David C. Lubner, Attorney-in-Fact for Alonso Ricardo	03/06/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.